Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Knight

Showing results (31-40 of 68) with videos related to

Pageof 7
Sort By:
Development (Cambridge, England)|November 29, 2013
A bi-modal function of Wnt signalling directs an FGF activity gradient to spatially regulate neuronal differentiation in the midbrainCarlene Dyer, Eric Blanc, Anja Hanisch, et al.
Experimental Hematology|September 25, 2012
GSK3 inhibition prevents lethal GVHD in miceGuy Klamer, Sylvie Shen, Emma Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromesMikkael A Sekeres, Jaroslaw P Maciejewski, Aristotle A N Giagounidis, et al.
Cancer Control : Journal of the Moffitt Cancer Center|January 24, 2007
Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United StatesThomas F Goss, Agota Szende, Caroline Schaefer, et al.
Biomedicines|October 23, 2021
Systems Analysis Reveals Ageing-Related Perturbations in Retinoids and Sex Hormones in Alzheimer's and Parkinson's DiseasesSimon Lam, Nils Hartmann, Rui Benfeitas, et al.
International Journal of Hematology|July 4, 2012
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myelomaAsher A Chanan-Khan, Sagar Lonial, Donna Weber, et al.
The New England Journal of Medicine|February 11, 2005
Efficacy of lenalidomide in myelodysplastic syndromesAlan List, Sandy Kurtin, Denise J Roe, et al.
The AAPS Journal|December 5, 2022
Stability and Function of Extracellular Vesicles Derived from Immortalized Human Corneal Stromal Stem Cells: A Proof of Concept StudyNing Lyu, Robert Knight, Sarah Y T Robertson, et al.
British Journal of Haematology|March 22, 2014
Sotatercept in patients with osteolytic lesions of multiple myelomaKudrat M Abdulkadyrov, Galina N Salogub, Nuriet K Khuazheva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasoneMaurizio Zangari, Guido Tricot, Latha Polavaram, et al.
Pageof 7

Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
Development (Cambridge, England)|November 29, 2013
A bi-modal function of Wnt signalling directs an FGF activity gradient to spatially regulate neuronal differentiation in the midbrainCarlene Dyer, Eric Blanc, Anja Hanisch, et al.
Experimental Hematology|September 25, 2012
GSK3 inhibition prevents lethal GVHD in miceGuy Klamer, Sylvie Shen, Emma Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromesMikkael A Sekeres, Jaroslaw P Maciejewski, Aristotle A N Giagounidis, et al.
Cancer Control : Journal of the Moffitt Cancer Center|January 24, 2007
Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United StatesThomas F Goss, Agota Szende, Caroline Schaefer, et al.
Biomedicines|October 23, 2021
Systems Analysis Reveals Ageing-Related Perturbations in Retinoids and Sex Hormones in Alzheimer's and Parkinson's DiseasesSimon Lam, Nils Hartmann, Rui Benfeitas, et al.
International Journal of Hematology|July 4, 2012
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myelomaAsher A Chanan-Khan, Sagar Lonial, Donna Weber, et al.
The New England Journal of Medicine|February 11, 2005
Efficacy of lenalidomide in myelodysplastic syndromesAlan List, Sandy Kurtin, Denise J Roe, et al.
The AAPS Journal|December 5, 2022
Stability and Function of Extracellular Vesicles Derived from Immortalized Human Corneal Stromal Stem Cells: A Proof of Concept StudyNing Lyu, Robert Knight, Sarah Y T Robertson, et al.
British Journal of Haematology|March 22, 2014
Sotatercept in patients with osteolytic lesions of multiple myelomaKudrat M Abdulkadyrov, Galina N Salogub, Nuriet K Khuazheva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasoneMaurizio Zangari, Guido Tricot, Latha Polavaram, et al.
Pageof 7